developed using same technology used in the development of Hib vaccine
the vaccine induces a T-cell dependent antibody response and immunological memory - it is protective in children under 2 years of age
carrier proteins used in MenC conjugate vaccines are tetanus toxoid or variant diphtheria toxin (CRM197)
the vaccine should be reconstituted immediately before use with the dilutent supplied by the manufacturer - once the vaccine has been reconstituted then it must be used within one hour
administered as a intramuscular or deep subcutaneous injection - in patients with bleeding disorders or thrombocytopaenia then the vaccine may be given subcutaneously
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page